Cost-effectiveness of nonavalent HPV vaccination in the Netherlands
Background A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed.Research design and methods We compared the public health and economic benefits of 2vHPV- and 9vHPV-based vaccination strategies in the Netherlands over 100 ...
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
Taylor & Francis Group
2024-12-01
|
| Reeks: | Expert Review of Vaccines |
| Onderwerpen: | |
| Online toegang: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2322543 |